Unique ID issued by UMIN | UMIN000003692 |
---|---|
Receipt number | R000004472 |
Scientific Title | Phase I/IIa clinical trial of Boron neutron Capture Therapy for the patients with recurrent malignant brain tumor |
Date of disclosure of the study information | 2010/06/01 |
Last modified on | 2012/06/26 09:46:13 |
Phase I/IIa clinical trial of Boron neutron Capture Therapy for the patients with recurrent malignant brain tumor
Phase I/IIa clinical trial of Boron neutron Capture Therapy for the patients with recurrent malignant brain tumor
Phase I/IIa clinical trial of Boron neutron Capture Therapy for the patients with recurrent malignant brain tumor
Phase I/IIa clinical trial of Boron neutron Capture Therapy for the patients with recurrent malignant brain tumor
Japan |
Recurrent malignant brain tumor
Radiology | Neurosurgery |
Malignancy
NO
To determine the safety and effectiveness of the boron neutron capture therapy for recurrent malignant brain tumor.
Safety,Efficacy
Exploratory
Explanatory
Phase I,II
Safety
Overall survival
Progression free survival
Tumor control rate, local control rate
QOL, neurological function
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
1
Treatment
Medicine | Device,equipment |
1)Boron compounds
250mg/kg of boronopehnylalanine, dose escalation was possible
2)Neutron irradiation
Less than 12Gy-Eq for normal brain and skin dose.
15 | years-old | <= |
70 | years-old | >= |
Male and Female
1) Agaed 15 and over, and 70 and under. Diagnosed as recurrent malignant glioma, recurrent malignant /anaplastic meningioma, malignant melanoma, and metastatic brain tumor or skull base tumor with no standard therapies.
2) Karnofsky Performance Scale(KPS) >50%
3) Enhance lesion locate within cerebral hemisphere. Infratentorial lesions without untreated hydrocephalus or brain stem compression.
4) The target lesion is located within 7cm from the brain surface.
5) Informed about their diagnosis.
6) course observation is possible.
1)Patient with dissemination.
2)AST,ALT > 100IU/ml , Bilirubin > 2.0mg%
BUN > 30mg/dl , Cr > 1.8mg%
WBC < 2500/mm3 , Plt < 75000/mm3 , Hb < 8g/dl
3)irradiated > 70Gy-Eq to the lesion or normal brain tissue as a previous treatment.
4)There are other malignanicies.
5)The patients with phenylcetonuria.
6)Patients who have complications that are considered inappropriate for the trial.
7)Responsible doctors judged the patient inappropriate for the trial.
20
1st name | |
Middle name | |
Last name | Akira Matsumura |
Institute of Clinical Medicine
Graduate School of Comprehensive Human Sciences
University of Tsukuba
Department of Neurosurgery
1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575 Japan
+81-298-53-3220
1st name | |
Middle name | |
Last name | Kei Nakai |
Institute of Clinical Medicine Graduate School of Comprehensive Human Sciences University of Tsukuba
Department of Neurosurgery
1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575 Japan
+81-298-53-3220
knakai@md.tsukuba.ac.jp
Department of Neurosurgery
Institute of Clinical Medicine
Graduate School of Comprehensive Human Sciences
University of Tsukuba
Ministry of Education, Culture, Sports, Science and Technology
Japan
NO
筑波大学附属病院(茨城県)
2010 | Year | 06 | Month | 01 | Day |
Unpublished
Terminated
2010 | Year | 03 | Month | 02 | Day |
2010 | Year | 06 | Month | 01 | Day |
2015 | Year | 06 | Month | 01 | Day |
2015 | Year | 06 | Month | 01 | Day |
2015 | Year | 06 | Month | 01 | Day |
2015 | Year | 12 | Month | 01 | Day |
2010 | Year | 06 | Month | 01 | Day |
2012 | Year | 06 | Month | 26 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004472